NVS

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -1.91
Percentage change -1.54	%

Peers: PFE MRK JNJ ABBV BMY LLY GILD AMGN REGN VRTX

| Held by: DFIV DFIC DFAI DFAX DIHP AVDE PPH FVD PID AVIV

Scroll to Statements

Index	-	P/E	19.08	EPS (ttm)	6.39	Insider Own	0.00%	Shs Outstand	1.96B	Perf Week	1.31%
Market Cap	231.32B	Forward P/E	13.45	EPS next Y	9.06	Insider Trans	-	Shs Float	1.90B	Perf Month	5.14%
Enterprise Value	255.47B	PEG	2.80	EPS next Q	2.34	Inst Own	7.34%	Short Float	0.20%	Perf Quarter	10.05%
Income	12.86B	P/S	4.47	EPS this Y	11.58%	Inst Trans	0.63%	Short Ratio	2.14	Perf Half Y	25.24%
Sales	51.72B	P/B	6.22	EPS next Y	3.97%	ROA	13.24%	Short Interest	3.87M	Perf YTD	25.27%
Book/sh	19.58	P/C	32.14	EPS next 5Y	6.81%	ROE	32.95%	52W High	124.45 -2.05%	Perf Year	14.42%
Cash/sh	3.79	P/FCF	13.14	EPS past 3/5Y	-17.95% 13.99%	ROIC	20.88%	52W Low	96.06 26.90%	Perf 3Y	53.05%
Dividend Est.	4.07 (3.34%)	EV/EBITDA	11.47	Sales past 3/5Y	-0.85% 1.16%	Gross Margin	74.46%	Volatility	1.14% 1.03%	Perf 5Y	47.90%
Dividend TTM	3.87 (3.17%)	EV/Sales	4.94	EPS Y/Y TTM	-13.28%	Oper. Margin	31.63%	ATR (14)	1.75	Perf 10Y	42.65%
Dividend Ex-Date	Mar 12, 2025	Quick Ratio	0.61	Sales Y/Y TTM	6.30%	Profit Margin	24.86%	RSI (14)	62.33	Recom	3.04
Dividend Gr. 3/5Y	14.94% 10.29%	Current Ratio	0.79	EPS Q/Q	39.37%	SMA20	2.38%	Beta	0.62	Target Price	124.13
Payout	55.39%	Debt/Eq	0.81	Sales Q/Q	11.87%	SMA50	6.24%	Rel Volume	0.53	Prev Close	123.81
Employees	75883	LT Debt/Eq	0.61	Earnings	Jul 17 BMO	SMA200	11.60%	Avg Volume	1.81M	Price	121.90
IPO	Nov 07, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.86% 1.15%	Trades		Volume	955,240	Change	-1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-25	Downgrade	UBS	Buy → Neutral
Feb-12-25	Initiated	Morgan Stanley	Underweight
Feb-04-25	Upgrade	Deutsche Bank	Hold → Buy
Dec-04-24	Downgrade	HSBC Securities	Hold → Reduce
Sep-11-24	Downgrade	BofA Securities	Buy → Neutral	$135 → $130
Sep-05-24	Downgrade	Goldman	Buy → Neutral
Sep-03-24	Downgrade	Jefferies	Buy → Hold
Jul-19-24	Downgrade	Deutsche Bank	Buy → Hold
May-30-24	Initiated	Goldman	Buy	$120
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-26-23	Upgrade	Deutsche Bank	Hold → Buy
Mar-27-23	Upgrade	Deutsche Bank	Sell → Hold
Jan-26-23	Downgrade	Citigroup	Buy → Neutral
Dec-05-22	Upgrade	Stifel	Hold → Buy
Sep-15-22	Downgrade	Credit Suisse	Neutral → Underperform

Show Previous Ratings

Jul-03-25 10:32AM	Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study (Zacks)
09:16AM	FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug (Zacks)
01:25AM	Novartis provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis (GCA) (PR Newswire)
Jul-02-25 09:44AM	Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start (Zacks)
Jul-01-25 09:33AM	Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? (Zacks)
09:15AM	Loading…
09:15AM	Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jun-26-25 02:04PM	Final Trades: Novartis, Sixth Street, Amazon and the IYF (CNBC TV)
Jun-25-25 04:19PM	Can Biogen Save Even More Kids With This New Drug? (Investor's Business Daily)
09:13AM	Novartis completes acquisition of Regulus Therapeutics (GlobeNewswire)
07:30AM	Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? (Investor's Business Daily)
01:00AM	Novartis announces expiration of Regulus Therapeutics tender offer (GlobeNewswire)
Jun-24-25 05:51PM	Novartis AG (NVS): A Bull Case Theory (Insider Monkey)
04:53PM	Top Analyst Reports for JPMorgan, Novartis & AT&T (Zacks)
Jun-23-25 01:00AM	Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer (GlobeNewswire)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
09:52AM	Loading…
09:52AM	Novartis ribociclib approved in Canada for early breast cancer (Pharmaceutical Technology)
08:55AM	NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth (PR Newswire)
Jun-19-25 01:30PM	FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
03:00AM	Gene Therapy Has Lost Support on Wall Street. Theres Still Hope for Big Cures. (Barrons.com)
Jun-18-25 10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
Jun-16-25 09:49AM	RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development (Zacks)
09:06AM	5 Large Drug Stocks That Are Poised to Ride on Sector Recovery (Zacks)
08:53AM	Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War (Zacks)
Jun-15-25 05:47AM	Berenberg Bank Maintains a Hold Rating on Novartis (NVS) (Insider Monkey)
05:46AM	Deutsche Bank Remains a Buy on Novartis (NVS) With a CHF115 PT (Insider Monkey)
Jun-13-25 12:45PM	Senators to propose ban on drug ads to consumers, WSJ reports (TipRanks)
09:15AM	Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue? (Zacks)
09:08AM	NVO Stock up on Plans to Advance Obesity Candidate Amycretin (Zacks)
07:16AM	Loading…
07:16AM	Novartis reports positive results from Phase IIIB study of iptacopan for PNH (Clinical Trials Arena)
Jun-12-25 08:43PM	Analyst Report: Novartis AG (Morningstar Research)
09:15AM	BMY Reports Positive Data on Sotyktu From Arthritis Study (Zacks)
02:00AM	Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH (GlobeNewswire)
Jun-11-25 10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
10:00AM	NVO Stock Gains After Parvus Asset Management Builds Stake (Zacks)
09:47AM	FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down (Zacks)
Jun-10-25 10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks)
04:00AM	The former Wall Street analyst shaping Novartis big-picture strategy (Pharma Voice)
Jun-09-25 09:50AM	Why Novartis (NVS) is a Top Momentum Stock for the Long-Term (Zacks)
09:40AM	Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:44AM	Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space (Zacks)
Jun-06-25 11:45AM	Novartis (NVS) Could Be a Great Choice (Zacks)
06:45AM	2 Dividend Growth Stocks to Buy and Hold Forever (Motley Fool)
Jun-03-25 12:11PM	Bristol Myers Collaborates With BNTX for Oncology Candidate (Zacks)
07:12AM	Novartis reports topline outcomes from trial of Pluvicto for prostate cancer (Clinical Trials Arena)
Jun-02-25 10:00AM	ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP (Clinical Trials Arena)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:38AM	Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study (Zacks)
08:44AM	Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure (Zacks)
03:19AM	Novartis' Pluvicto shown to slow prostate cancer in earlier setting (Reuters)
02:04AM	Novartiss Cancer Treatment Pluvicto Shows Positive Results in Trial (The Wall Street Journal)
01:15AM	Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (GlobeNewswire)
Jun-01-25 09:00AM	Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis (GlobeNewswire)
May-30-25 10:15AM	Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment (Zacks)
May-27-25 09:55AM	What Makes Novartis AG (NVS) a Differentiated Business? (Insider Monkey)
07:56AM	Novartis announces commencement of tender offer to acquire Regulus Therapeutics (GlobeNewswire)
May-26-25 09:16AM	GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer (Zacks)
May-23-25 04:09PM	Regeneron Initial Data on Multiple Myeloma Drug Encouraging (Zacks)
04:02PM	Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication (Zacks)
May-21-25 11:45AM	Are You Looking for a High-Growth Dividend Stock? (Zacks)
May-20-25 06:28AM	Pfizer Signs Experimental Drug Licensing Agreement With 3SBio (Zacks)
06:00AM	Companies Are Planning to Build Factories In America. Are Trump's Tariffs Working? (Investopedia)
May-19-25 04:58AM	Judge shuts down drugmakers 340B rebate plans, for now (Healthcare Dive)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks)
09:40AM	Here's Why Novartis (NVS) is a Strong Value Stock (Zacks)
May-15-25 12:00PM	Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Should Value Investors Buy Novartis (NVS) Stock? (Zacks)
09:00AM	New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline (GlobeNewswire)
07:55AM	GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug (Zacks)
May-13-25 08:21AM	RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US (Zacks)
May-12-25 06:14PM	Drugmakers Spared Worst-Case Drug Pricing Scenario for Now (The Wall Street Journal)
06:14PM	Drugmakers Avoid Worst-Case Pricing Scenario for Now (The Wall Street Journal)
04:56PM	Analyst Report: Novartis AG (Morningstar Research)
07:33AM	Trumps Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks (The Wall Street Journal)
03:19AM	Novartis to keep making malaria drugs if orders dry up amid aid cuts (Reuters)
May-09-25 09:50AM	Here's Why Novartis (NVS) is a Strong Momentum Stock (Zacks)
May-08-25 07:42AM	Q1 2025 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... (GuruFocus.com)
May-07-25 02:14PM	Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating (Seeking Alpha)
May-05-25 12:50PM	Fidelity International Discovery Fund Q1 2025 Commentary (Seeking Alpha)
12:00PM	Novartis (NVS) is a Great Momentum Stock: Should You Buy? (Zacks)
11:45AM	Why Novartis (NVS) is a Great Dividend Stock Right Now (Zacks)
May-03-25 04:51AM	The Play On Legend Biotech (Seeking Alpha)
May-02-25 10:51AM	Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y (Zacks)
09:39AM	Novartis to buy Regulus Therapeutics for as much as $1.7 billion (LA Times)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
10:42AM	Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View (Zacks)
07:26AM	Novartis to strengthen renal disease portfolio with Regulus (Pharmaceutical Technology)
Apr-30-25 11:50PM	Franklin Global Equity Fund Q1 2025 Commentary (Seeking Alpha)
10:00PM	Franklin Mutual International Value Fund Q1 2025 Commentary (Seeking Alpha)
04:30PM	Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (Seeking Alpha)
09:46AM	Novartis: 2025 Guidance Raised To Top End Of Prior Range - Buy Confirmed (Seeking Alpha)
09:40AM	Why Novartis (NVS) is a Top Value Stock for the Long-Term (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
08:15AM	Novartis to acquire Regulus in deal for kidney disease drug (BioPharma Dive)
08:04AM	Stocks to Watch Wednesday: Humana, Snap, Visa, Super Micro (The Wall Street Journal)
07:50AM	Novartis to Acquire Regulus in $1.7 Billion Deal (The Wall Street Journal)
07:24AM	Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal (Reuters)
07:10AM	Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure (GlobeNewswire)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Marshall Fiona	Officer	May 23 '25	Proposed Sale	112.68	15,000	1,690,181	May 23 03:40 PM
Kowalski Robert William	Officer	Apr 30 '25	Proposed Sale	113.28	1,212	137,297	Apr 30 01:52 PM
Kowalski Robert William	Officer	Aug 12 '24	Proposed Sale	111.72	6,566	733,572	Aug 12 03:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novartis AG ADR

Upgrade your FINVIZ experience